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Motor neuron (MN) degeneration is the pathological hallmark of MN diseases, a
group of neurodegenerative disorders clinically manifested as muscle fasciculations
and hyperreflexia, followed by paralysis, respiratory failure, and death. Ample evidence
supports a role of glutamate-mediated excitotoxicity in motor death. In previous work
we showed that stimulation of glutamate release from nerve endings by perfusion of
the K+-channel blocker 4-aminopyridine (4-AP) in the rat hippocampus induces seizures
and neurodegeneration, and that AMPA infusion in the spinal cord produces paralysis
and MN death. On these bases, in this work we have tested the effect of the chronic
infusion of 4-AP in the spinal cord, using implanted osmotic minipumps, on motor activity
and on MN survival, and the mechanisms underlying this effect. 4-AP produced muscle
fasciculations and motor deficits assessed in two motor tests, which start 2–3 h after the
implant, which ameliorated spontaneously within 6–7 days, but no neurodegeneration.
These effects were prevented by both AMPA and NMDA receptors blockers. The role of
GABAA receptors was also explored, and we found that chronic infusion of bicuculline
induced moderate MN degeneration and enhanced the hyperexcitation produced by
4-AP. Unexpectedly, the GABAAR agonist muscimol also induced motor deficits and
failed to prevent the MN death induced by AMPA. We conclude that motor alterations
induced by chronic 4-AP infusion in the spinal cord in vivo is due to ionotropic glutamate
receptor overactivation and that blockade of GABAergic neurotransmission induces MN
death under chronic conditions. These results shed light on the role of glutamatergic and
GABAergic neurotransmission in the regulation of MN excitability in the spinal cord.
Keywords: motor neuron degeneration, excitotoxicity, spinal cord, 4-aminopyridine, glutamate receptors, GABAA
receptor
INTRODUCTION
Motor neuron (MN) degeneration in the spinal cord and/or in the cerebral cortex is the
common pathological hallmark of MN diseases, which include a wide spectrum of heterogeneous
neurodegenerative disorders. The loss of MNs leads to characteristic symptoms: initially
hyperreflexia, muscle fasciculations, fatigue, weakness, cramps and later paralysis, and respiratory
failure. Amyotrophic lateral sclerosis (ALS), spinal muscular atrophy, and spinal and bulbar
muscular atrophy are some examples of MN disorders and, although having a relatively
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low prevalence, they all cause great morbidity and are uniformly
fatal (Tiryaki and Horak, 2014). In spite of extensive research,
no common cause of this selective MN degeneration has been
identified and several hypotheses have been proposed, including
glutamate-mediated excitotoxicity, mitochondrial dysfunction
and energy failure, protein aggregation, endoplasmic reticulum
stress, and RNA metabolism aberrations, among others (Dion
et al., 2009).
Glutamate-mediated excitotoxicity is a key mechanism
in neuronal death in most experimental models of MN
disorders. It is possible to elicit excitotoxic neuronal death by
different mechanisms, including: (1) pharmacological blockade
of glutamate uptake; (2) stimulating endogenous glutamate
release; and (3) overactivation of postsynaptic AMPA and
NMDA types glutamate receptors (Mehta et al., 2013). Previous
work from our group has established the differential efficacy
of these strategies in triggering neurodegeneration in several
regions of the rat nervous system in vivo. We have repeatedly
shown that the infusion of the glutamate transport blocker
pyrrolidine dicarboxylic acid by microdialysis or osmotic
minipumps fails to provoke hyperexcitation and neuronal
degeneration, even when inducing remarkable increases (up to
20-fold) in extracellular glutamate concentration, in the striatum
(Massieu et al., 1995), hippocampus (Peña and Tapia, 1999),
cerebral cortex (Tovar-y-Romo and Tapia, 2006), and spinal
cord (Corona and Tapia, 2004; Tovar-y-Romo et al., 2009a). In
the hippocampus, such increase due to transport blockade may
even paradoxically protect against excitotoxicity due to inhibition
of glutamate release by activation of presynaptic metabotropic
glutamate receptors (Vera and Tapia, 2012).
Conversely, infusing 4-AP in vivo through microdialysis
triggers behavioral and electroencephalographic seizures, as
well as excitotoxic neuronal death, in the rat striatum
(Morales-Villagran and Tapia, 1996) and hippocampus (Peña
and Tapia, 1999, 2000). These effects are caused by a transient
stimulation of the release of endogenous glutamate from
nerve endings and the consequent overactivation of glutamate
receptors, as demonstrated by the potent protective effect of the
NMDA receptor antagonists MK-801 and CPP, and of the AMPA
receptor antagonist NBQX.
4-AP perfusion bymicrodialysis in the lumbar spinal cord also
induced a notable transient (30min) increase in the extracellular
concentration of glutamate as well as motor behavioral effects,
such as fasciculations, twitching and muscle cramps in the
hindlimbs, for up to 2 h, even when the rats were anesthetized,
suggesting a muscular hyperexcitability state analogous to that of
seizures; however, no significant MN degeneration was observed.
In contrast, the microdialysis perfusion of AMPA induced MN
death and hindlimb paralysis (Corona and Tapia, 2004), effects
that were prevented by specific blockers of the Ca2+-permeable
AMPA receptors and by intracellular Ca2+ chelators (Corona
and Tapia, 2007). Since these excitotoxic effects induced by the
Abbreviations: NMDAR, N-methyl-D-aspartate glutamate receptor; AMPAR, α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionate glutamate receptor; GABAAR,
γ-aminobutyric acid type A receptor; 4-AP, 4-aminopyridine; MN, Motor neuron;
ALS, Amyotrophic lateral sclerosis.
microdialysis perfusion occur very rapidly, in less than 12 h, we
developed a different model by chronically infusing drugs during
several days through osmotic minipumps directly in the lumbar
spinal cord tissue in behaving rats (Tovar-y-Romo et al., 2007). In
this chronic experimental setting we showed that chronic AMPA
receptor activation also induces MN degeneration and bilateral
paralysis, while, as previously stated, glutamate uptake blockade
does not cause MN degeneration even with a 12-fold increase
in extracellular glutamate concentration (Tovar-y-Romo et al.,
2009a).
In view of the above results, we considered relevant to
elucidate if the chronic administration of 4-AP through osmotic
minipumps in the spinal cord is also capable of eliciting MN
degeneration and paralysis. We found that this chronic 4-AP
infusion caused motor behavior deficits during several days and
muscular signs of hyperexcitation, but since noMN degeneration
or paralysis occurred we hypothesized that this might be due
to a combined activation of both excitatory glutamatergic input
on MNs and of GABAergic local inhibitory spinal circuits,
whose function as modulators of motor activity has been clearly
established (Martin and Chang, 2012; Ramirez-Jarquin et al.,
2014). In fact, we and others have shown that the stimulatory
action of 4-AP on the release of neurotransmitters is not specific
for glutamate but involves also GABA (Jankowska et al., 1977;
Morales-Villagran and Tapia, 1996; Peña and Tapia, 1999).
Therefore, we also tested the effect of the GABAAR antagonist
and agonist bicuculline and muscimol, respectively, on the
excitotoxic effects of both 4-AP and AMPA. Our results indicate
that chronic alterations of GABAergic neurotransmission are
notably involved in the 4-AP-induced hyperexcitation mediated
by overactivation of glutamate receptors and that may induce
MN death.
MATERIALS AND METHODS
Animals
Adult Wistar male rats (280–300 g) were used in all of
the experiments and were handled in accordance with the
Rules for Research and Health Matters (Mexico) and with
international standards of research animal welfare (including
ARRIVE guidelines), and with approval of the Institutional
Committee for the Care andUse of Laboratory Animals (protocol
approval number RTI21-14). All animals were housed in a
controlled laboratory environment with a 12 h light/dark cycle,
and fed with regular animal chow and water ad libitum. All
surgical procedures were performed under general anesthesia,
and every effort was made to minimize animal suffering during
experimental procedures.
Drugs and Osmotic Minipump Preparation
All drugs were dissolved in isotonic saline solution (SS). Osmotic
minipumps (Alzet model 2004, volume ∼250 µL, flow rate 6
µl/day) were filled with the different solutions containing the
used drugs at the following concentrations: SS as control, AMPA
7.5mM, 4-AP 35mM, MK-801 1mM, NBQX 1mM, bicuculline
methbromide 5mM, muscimol 10mM, or a mixture of drugs,
as indicated in Results, 48 h before the surgical implantation,
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and were incubated at 37.0◦ in SS for flow rate stabilization.
These concentrations were chosen on the basis of previous results
from our laboratory (Peña and Tapia, 1999, 2000; Corona and
Tapia, 2004; Tovar-y-Romo et al., 2007) and of preliminary
experiments. AMPA, MK801, and NBQX were purchased from
Tocris Bioscience, and 4-AP, bicuculline methbromide, and
muscimol from Sigma Aldrich.
Surgical Osmotic Minipump Implantation
The procedure for osmotic minipump implantation was
performed essentially as previously described (Tovar-y-Romo
et al., 2007), with minor modifications. Briefly, animals were
anesthetized with 5.0% isoflurane in a 95% O2/5% CO2 mixture
and placed in a stereotaxic spinal unit. Later on, isofluorane
concentration was gradually diminished to 1.5–2.0% as the
surgery was performed. After shaving and disinfection, a median
sagittal incision, 3.5–4 cm long, was made in the back of the
animal and the underlying fascia andmuscle tissue were dissected
until appropriate visualization of the T10 vertebral lamina was
achieved (at the spinal L3 level). The spinous process was
removed with a drill, and a ∼2mm diameter hole was drilled in
the right lamina until the spinal cord tissue was visualized and
the meninges were carefully removed with a metallic hook. A
stainless-steel screw (3.7mm long, 1mm diameter) was fixed in
the left lamina. A fused silica glass filament probe (1mm long, 50
µm internal diameter, 80 µm external diameter, VitroCom Inc.)
was carefully advanced down into the spinal cord in a vertical
fashion with the aid of the three-dimensional manipulator of
the stereotaxic unit; previously, this glass probe was attached
and glued to a plastic tubing ∼1 cm long, and during surgery
this tube was connected and fixed with cyanoacrylate glue to
the osmotic minipump. During all these procedures great care
was taken to avoid damage to the spinal cord tissue. Dental
cement was poured and let dry on the T10 vertebra, to fix both
the screw and the cannula on place. Osmotic minipumps were
subcutaneously placed in the back of the animal, at the right
side of the vertebral column. This procedure aims to directly and
continuously administer the tested drugs in the spinal cord tissue,
at a rate of 0.25 µl/h up to 25 days, in the vicinity of lamina IX,
where motor neurons reside. Finally, the skin incision was closed
with surgical stainless-steel clips, anesthesia was withdrawn, and
animals received a single intraperitoneal antibiotic shot and were
monitored until full consciousness was recovered.
Behavioral Assessment
Four to five days prior to surgery, rats were trained to walk
during 120 s on an accelerating Rotarod (Columbus Instruments,
USA), starting from 10 rpm (0.2 rpm/s of acceleration). Time to
fall from the instrument was recorded, up to a limit of 120 s.
Also, grip strength of both hind limbs was measured by placing
the animals on their hind limbs on the metallic mesh of a grip
strength meter (TSE Systems, USA) and gently pulling the tail to
induce the animals to escape from the examiner; measurement
was not considered if the animals, when attempting to escape,
used their forelimbs. The maximum force displayed by the
instrument in every trial was recorded in ponds, later converted
to Newtons (1 pond = 0.009807 N), and normalized to values
obtained the day before surgery (day 0). In both tests the best
time, or the greater force, out of three trials was recorded. Great
care was taken to avoid excessive distress in the animals, and
appropriate time between trials was given to the animals to rest.
These behavioral motor tasks were assessed on a daily basis for 5
or for 15 days (depending on the experiment) and, on these cutoff
times, animals were sacrificed and fixed/perfused for histology.
Histological Processing
After the time for behavioral assessment was concluded,
rats were perfused and fixed for histological analyses as
previously described (Tovar-y-Romo et al., 2007). Briefly,
animals were deeply anesthetized with an intraperitoneal
injection of pentobarbital, the rib cage was cut to expose the
heart, and a wide cut in the right atria was made. A needle,
connected to a peristalsis pump, was inserted into the left
ventricle and ∼250ml of ice cold normal saline were perfused,
followed by∼250ml of 4% paraformaldehyde in 0.1M phosphate
buffer. The back was dissected, the acrylic implant removed, and
the lumbar spinal cord tissue was recovered by pushing it out of
the vertebral canal with cold saline solution in a syringe. Tissue
was postfixed for 48 h at 4.0◦C, then dehydrated in increasingly
concentrated sucrose solutions (10, 20, and 30%), and the region
where the cannula was inserted was visually identified and used
for study. Approximately 50 transverse sections (40 µm thick)
were obtained in a cryostat, and the slices that showed the fused
silica filament entry point were used for analyses and, of these,
15–20 slices were stained with cresyl violet (Nissl staining) for
further analysis. The number of morphologically healthy MNs
(multipolar neurons with clear cytoplasm, soma diameter >20
µm and distinguishable nucleus) was counted in the ipsilateral
and contralateral ventral horns.
Statistical Analysis
All statistical analyses were carried out in GraphPad Prism 5
using a twowayANOVA (in the case of behavioral tasks) followed
by a Bonferroni’s post-hoc test, or a one way ANOVA (for number
of healthy MN) followed by a Tukey’s post-hoc test. A value of
p < 0.05 was considered statistically significant.
RESULTS
Chronic 4-AP Infusion Induces Motor
Behavior Alterations, that are Enhanced by
Bicuculline
4-AP infusion caused motor behavior alterations in the
hindlimbs of treated animals manifested as episodic muscle
cramps and fasciculations that appeared frequently in the
ipsilateral hindlimb. Animals seemed distressed when these
alterations occurred, since they squealed, compulsively groomed
the affected hindlimb, and even removed the overlying fur, and
had occasional running fits. These episodic alterations started
within 3 to 5 h after minipump implantation and lasted a few
minutes with a variable frequency, but were often observed
during or immediately after the rotarod tests. They progressively
diminished in frequency, duration and intensity up to day 7 to
10, and subsequently were rarely observed.
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These motor alterations were evidenced in the rotarod test
as a progressive, but transitory, reduction in the time to fall,
reaching significant difference only at day 5; in the grip strength
assessment there were no changes, although we observed a slight
non-significant increase in grip strength from day 10 until 15
(Figures 1A,B, top row). MK-801 co-infused with 4-AP almost
completely prevented the fasciculations and muscle cramps
induced by 4-AP, although the rotarod test and the hindlimb
grip strength assessment did not show significant differences with
respect to 4-AP alone (Figures 1A,B, bottom row). NBQX co-
infused with 4-AP also partially suppressed the overexcitation
induced by 4-AP and, again, the results obtained from the motor
behavioral tasks were very similar to those of 4-AP treatment
(Figure 1, bottom row). NBQX and M801 alone did not affect
any of the parameters studied (not shown).
Then we tested the effect of bicuculline to explore the role
of GABAAR in the 4-AP-induced motor alterations. Animals
treated with bicuculline alone displayed only slight behavioral
changes, such as occasional grooming and licking of the
ipsilateral hindlimb, and did not alter significantly the rotarod
performance nor the hindlimb grip strength. Co-infusion of
bicuculline with 4-AP enhanced the intensity of fasciculations
and the frequency of grooming induced by 4-AP; this was
reflected in a decrease in the time to fall from the rotarod and in
a trend to reduce the strength values as compared to 4-AP alone
(Figure 1, middle row).
Bicuculline, but Not 4-AP, Induces MN
Degeneration
In spite of the motor behavioral changes obtained with 4-AP
infusion we did not find loss of MNs when we assessed the
spinal cord tissue with Nissl staining (20.9 ± 3.1 vs. 19.3 ± 4.1
MNs ipsilateral side; 21.8 ± 2.7 vs. 21.1 ± 5.3 MNs contralateral
side, compared to control). Neither NQBX nor MK-801, alone or
in combination with 4-AP, altered the number of healthy MNs
(Figures 2A,B). However, unexpectedly, bicuculline infusion
FIGURE 1 | Behavioral effects of chronic 4-aminopyridine infusion in the rodent spinal cord in vivo. (A) Results of rotarod test performance expressed as
the time to fall (in seconds) in each of the experimental conditions. Top, 4-AP infusion causes a reversible decrease in the time to fall significantly different to Control
only at day 5 (two-way ANOVA, Bonferroni’s post-hoc; *p < 0.05). Middle, bicuculline treatment did not result in significant changes, while 4-AP + bicuculline
co-infusion produced an irreversible reduction in the time to fall, different to Control at days 5 and 15, and to 4-AP at day 15 (two-way ANOVA, Bonferroni’s post-hoc;
*p < 0.05 vs. control; p < 0.05 vs. 4-AP). Bottom, Co-infusion of NBQX or of MK-801 with 4-AP partially improved time to fall, attaining results not different from
Control or from 4-AP. (B) Results of hindlimb strength assessment normalized to baseline values (day 0, before osmotic minipump implantation). Top, Control group
displayed a gradual increase in strength up to a ∼10% at day 15 respect to baseline values, while 4-AP also displayed a non-significant gradual increase in strength
up to ∼30% at day 15. Middle, bicuculline treatment did not result in changes in strength in the 15 days of evaluation, while co-infusion of 4-AP + bicuculline resulted
in a tendency to decrease strength during the 15 days of treatment, reaching significance only at day 5 (two-way ANOVA, Bonferroni’s post-hoc; *p < 0.05 vs.
Control). Bottom, Co-infusion of NBQX or of MK-801 with 4-AP did not result in changes in strength.
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caused a significant ∼38% loss of MNs in the ipsilateral ventral
horn with respect to control (13.1 ± 4.5 vs. 20.9 ± 3.1 MNs) and
a ∼25% reduction in the contralateral side (16.4 ± 4.1 vs. 21.8 ±
2.7 MNs); this reduction was also significant with respect to 4-
AP alone, albeit only in the ipsilateral side. Co-infusion of 4-AP
with bicuculline resulted in loss of MNs similar to that caused by
bicuculline alone.
Chronic GABAAR Activation with Muscimol
Does Not Prevent Paralysis Induced by
AMPA Receptor Overactivation
The above results indicate that 4-AP infusion produce a
glutamate-receptor-mediated motor hyperexcitability state in
the spinal cord in vivo albeit not sufficient to induce MN
degeneration, whereas blockade of GABAAR was deleterious. So,
to test the role of GABA-mediated inhibition in the excitotoxic
effect of glutamate receptor overactivation, we infused muscimol
alone or in combination with AMPA. Muscimol treatment
provoked severe and long-lasting weakness in both hindlimbs,
that in some animals manifested as paralysis with no other
phenomena (such as autotomy, as is the case of AMPA-treated
animals), starting at day 1 or 2, that progressively recovered
throughout the 15 days’ timeline but never reached control values
again. Such motor alterations decreased the time to fall from
rotarod significantly at days 3, 4, and 5 (Figure 3A), as well as
a similar significant reduction in the grip strength at days 3, 4, 5,
and 10 (Figure 3B).
As previously described (Tovar-y-Romo et al., 2007), chronic
AMPA infusion induced a gradual and irreversible paralysis of
the hindlimbs of all treated animals, manifested in the motor
behavioral tasks as a progressive and irreversible diminution in
the time to fall from rotarod and as reduction in the strength in
both hindlimbs. The paralysis started on day 1 with the ipsilateral
hindlimb and gradually progressed up to day 5, when animals
were completely paralyzed in both hindlimbs. In this group, the
experiments were stopped at day 5 because animals could no
longer feed themselves and started to autotomize their hindlimbs.
When muscimol was co-infused with AMPA, we observed an
earlier onset and more severe paralysis, and an earlier, and
greater reduction of the time to fall and in grip strength as
compared to AMPA treatment, but no animals in this group
displayed autotomy, as opposed to the AMPA-alone group. The
values obtained were significantly different from control and
from muscimol-alone treatment in both tasks (Figures 3A,B,
respectively).
Chronic GABAAR Activation with Muscimol
Does Not Prevent MN Degeneration
Induced by AMPA
Histological analysis showed that muscimol infusion induced a
non-significant slight reduction in MN number. In contrast, as
expected, after AMPA infusion the paralysis observed correlated
with the previously reported almost total loss of MNs (Tovar-y-
Romo et al., 2007). Co-infusion with muscimol did not modify
the remarkable MN degeneration induced by AMPA (Figure 4).
DISCUSSION
Excitotoxicity, a fundamental mechanism of MN degeneration,
can be elicited by perturbing the presynaptic physiology in
two means: (1) blocking the uptake of released glutamate, or
(2) stimulating endogenous glutamate release. For the former,
although there is evidence that implicate it as a mechanism
of excitotoxic death in human MN disease (Rothstein et al.,
1992), experimental studies using genetic knockout of the GLT1
glutamate transporter in mice have failed to causally link this
finding to MN degeneration (Stoffel et al., 2004). Indeed, as
was stated in the Introduction, work done by our group do not
support glutamate uptake inhibition as an important mechanism
in models of neurodegeneration in vivo in several regions
FIGURE 2 | Results of MN counting in the lumbar spinal cord after 15 days of 4-AP infusion and other compounds in the spinal cord in vivo. (A)
Bicuculline-alone and 4-AP + bicuculline treatments induce a reduction in the number of MNs of similar magnitude (one-way ANOVA, Bonferroni’s post-hoc;
*p < 0.001 vs. Control), while 4-AP infusion and the other shown treatments did not produce changes in the number of MNs. (B) Representative high-magnification
microphotographs of Nissl-stained spinal ventral horns, where motor neurons reside (large, multipolar, intensely stained neuronal somas with prominent nuclei) after 15
days of the indicated treatments. Upper row show images of the ipsilateral side to the indicated infusion, and lower row show images of the contralateral side. (Scale
bar, 250 µm).
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FIGURE 3 | Behavioral effects of chronic muscimol and AMPA infusion in the rodent spinal cord in vivo. (A) Results of rotarod test performance expressed
as the time to fall in each of the experimental conditions. Muscimol causes a progressive reduction in the time to fall, which reverts late in the experimental timeframe
of 15 days (two-way ANOVA, Bonferroni’s post-hoc; *p < 0.05 vs. Control), while AMPA infusion results in more severe and irreversible reduction in the time to fall in
the 5 days of treatment. AMPA+muscimol coinfusion results in a further reduction in the time to fall, with an earlier onset, and also irreversible in nature (two-way
ANOVA, Bonferroni’s post-hoc; *p < 0.05 vs. Control; #p < 0.05 vs. muscimol). (B) Results of hindlimb strength assessment normalized to baseline values (day 0,
before osmotic minipump implantation). Muscimol infusion also induces a reduction in hindlimb strength that reverts late in the experiment (two-way ANOVA,
Bonferroni’s post-hoc; *p < 0.05 vs. Control), while AMPA and AMPA+muscimol infusions cause an irreversible, progressive and severe decline in the baseline
strength (two-way ANOVA, Bonferroni’s post-hoc; *p < 0.05 vs. control; #p < 0.05 vs. muscimol).
FIGURE 4 | Results of MN counting in the lumbar spinal cord after muscimol and AMPA infusions in the spinal cord in vivo. (A) 5 days of AMPA and
AMPA + muscimol treatments caused a significant reduction in the number of healthy MNs, while 15 days of muscimol infusion did not change MN number (one-way
ANOVA, Bonferroni’s post-hoc; *p < 0.001 vs. Control). (B) Representative high-magnification microphotographs of Nissl-stained spinal ventral horns after 15 days of
muscimol infusion, or after 5 days of the indicated treatments. Upper row show images of the ipsilateral side to the indicated infusion, and lower row show images of
the contrateral side. (Scale bar, 250 µm).
of the rodent central nervous system in an acute (Massieu
et al., 1995; Corona and Tapia, 2004; Tovar-y-Romo and Tapia,
2006) or in a chronic setting (Tovar-y-Romo et al., 2009b).
In the present work we have used the later strategy in a
chronic model of 4-AP administration in the spinal cord, in
view that its acute perfusion caused behavioral evidence of
hyperexcitability (muscle fasciculations and cramps), although
animals were anesthetized, but noMN degeneration even when it
transitorily stimulated up to 5-fold glutamate release immediately
after its administration (Corona and Tapia, 2004). In addition,
these results contrast with our previous findings showing that
infusing 4-AP through microdialysis stimulates the release of
endogenous glutamate and triggers immediate behavioral and
EEG seizure activity and delayed excitotoxic glutamate-mediated
neuronal death in the rat striatum (Morales-Villagran and Tapia,
1996) and hippocampus (Peña and Tapia, 1999, 2000). The
effects of 4-AP on extracellular glutamate in the hippocampus
were achieved almost immediately after its administration, and
persistent activation (for at least 60min) of the NMDA glutamate
receptor is required for neuronal death (Ayala and Tapia,
2005).
Our present results show that, similarly to the acute
administration, chronic 4-AP treatment in vivo failed to provoke
spinal MN death and paralysis, although it did result in
a hyperexcitability state manifested as muscle cramps and
fasciculations. Though in this work we did not directly measure
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the frequency or intensity of those behavioral manifestations,
these were enough to provoke changes in either behavioral motor
tasks: in rotarod as a trend toward a decrease in the time to fall,
and in hindlimb grip assessment as a trend toward an increase
in strength, which reached a maximum at day 5. Although
MN number was assessed after 15 days of continuous 4-AP
infusion, and no changes observed, it is difficult to envisage
that MN degeneration could occur at 5 days but not being
detected at 15 days. In order to confirm that these results are
secondary to an increase in glutamatergic neurotransmission,
suggestively due to 4-AP-mediated stimulation of endogenous
glutamate release, we examined the NMDA and AMPA types
glutamate receptors and found that their chronic blockade
prevented the motor behavior late in the experiment (until
day 3–5). Therefore, our data indicate that glutamatergic
neurotransmission in enhanced in the spinal cord by 4-AP,
and that this may account for the behavioral hyperexcitability
observed. The importance of glutamatergic transmission in the
excitability control of spinal cord MNs is well established, both
for the NMDA (Kudo and Yamada, 1987) and AMPA receptors
(Pook et al., 1993), albeit these data were obtained through in
vitro preparations.
Endogenous glutamate is not the only neurotransmitter
which release is stimulated by 4-AP infusion, as GABA release
has also been demonstrated by our group in the striatum
(Morales-Villagran and Tapia, 1996), hippocampus (Peña and
Tapia, 1999), and spinal cord (Corona and Tapia, 2004) in
vivo. So, we hypothesized that endogenous GABA, and the
consequent activation of its GABAAR, might counterbalance
the potential neurotoxic effects of 4-AP-induced release of
endogenous glutamate. The data we obtained from bicuculline
treatment demonstrates the neurotoxic properties of chronic
GABAAR blockade for the spinal cord MNs, though they
neither develop as rapidly or as severe, both in motor
behavior and in MN loss, as chronic AMPA infusion (Tovar-
y-Romo et al., 2007). The behavioral data also reveal that
GABAAR blockade potentiates the excitatory effect of 4-
AP, but this is insufficient to enhance the bicuculline-
induced MN degeneration. Thus, it seems that GABAAR
activation due to 4-AP-released endogenous GABA has no
role in the lack of neurotoxic action of chronic 4-AP
treatment.
This finding was unanticipated, since GABAAR activation
has consistently shown to be protective in models of
neurodegenerative disorders where excitotoxicity has an
important role (Rudolph and Knoflach, 2011). Also, GABAARs
are expressed in spinal MNs (Bohlhalter et al., 1996), play
an important role exerting tonic inhibition (Castro et al.,
2011), and their activity has been implicated in MN disease
(Ramirez-Jarquin et al., 2014). Indeed, several alterations in the
GABA-mediated inhibitory control of synaptic excitability
have been reported in models of MN disease: changes
in subunit composition and ligand affinity (Carunchio
et al., 2008) and decrease in GABAAR expression (Petri
et al., 2003). These data suggest that inhibitory GABAergic
neurotransmission failure may contribute to MN degeneration.
Our results with bicuculline are in agreement with this
statement, and are supported by a recent report in another
in vivo model of MN excitotoxic death induced by a single
intrathecal administration of NMDA and bicuculline (Ionov and
Roslavtseva, 2012).
Since excitotoxicity implies an imbalance in excitatory and
inhibitory inputs, with a resulting exaggeration of excitatory
drive, we assumed that restoring inhibition by pharmacologically
overactivating GABAAR in MNs might prevent the AMPA-
mediated degeneration. We found that muscimol did not result
in an amelioration of excitotoxic MN degeneration, although it
prevented the muscle cramps and hindlimb autotomy induced
by AMPA. In addition, we noticed an acceleration of paralysis
progression as manifested by a steeper decline in the time
to fall and in the hindlimb grip strength values. We suggest
that the overwhelming inhibitory drive produced by muscimol
induced a “functional paralysis,” without affecting the AMPA
receptor activation causing MN degeneration. This conclusion
is supported by the behavioral partial paralysis induced by
treatment with muscimol alone. Although the duration of
muscimol infusion was different from the AMPA + muscimol
infusion, it is possible to compare both treatments because no
MN death was observed after 15 days of muscimol alone, while
MN loss was almost complete after only 5 days of AMPA +
muscimol. Therefore, no further neuronal loss were probable
after 5 days. To the best of our knowledge, this is the first report
on the effects of GABAAR activation in the spinal cord in vivo,
and indicates that inhibitory neurotransmission fails to prevent
the excessive excitation caused by glutamate AMPA receptor
overactivation. Another way to test the role of GABAergic
neurotransmission in conditions of excessive excitatory drive
would be to infuse 4-AP and muscimol, but muscimol would
only add to the GABAAR activation already being achieved
by the 4-AP-mediated release of endogenous GABA, and
therefore the contribution of GABAAR activation could not
be distinguished by this co-infusion. These results are largely
in agreement with our previous work demonstrating a lack
of protective effect of GABAergic neurotransmission-facilitating
drugs in the NMDAR-dependent 4-AP-induced seizures and
neurodegeneration in the hippocampus in vivo (Peña and Tapia,
2000), and with the lack of amelioration of clinical severity
with the use of GABAergic drugs in ALS patients (Miller et al.,
2001).
Although it might be possible that the stimulation of the
release of other neurotransmitters may exert protective roles on
spinal MNs in vivo (Ramirez-Jarquin et al., 2014) we did not
explore that possibility. For instance, alterations in dopaminergic
(Borasio et al., 1998) and serotonergic and noradrenergic (Bertel
et al., 1991) neurotransmission have been documented in ALS
patients, but there is scarce evidence of their role in excitotoxic
MN degeneration. We propose that hyperexcitation produced
only through direct receptor modulation (either inhibitory
receptor blockade or excitatory receptor activation) may have
a causal role in excitotoxic MN death, at least in relevant in
vivo models. In view of our present, and of previous findings, it
is challenging to establish a unifying model for the presynaptic
mechanisms of excitotoxicity mediated by 4-AP throughout the
mammalian nervous system. Better methodological strategies are
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necessary to dissect simultaneously the role of the many (if not
every) neurotransmitter systems involved in the effects of 4-AP
across the central nervous system.
In summary, we found that chronic 4-AP infusion in the
spinal cord in vivo does not elicit MN degeneration but
does produce motor behavior alterations, and these partially
depend on ionotropic glutamate receptor activation, indicating
that they are due to endogenous glutamate released by 4-
AP. Also, we established that chronic GABAAR blockade
produces MN degeneration and that this effect is not potentiated
by 4-AP. However, chronic GABAAR activation produces
transitory paralysis, probably because of overinhibition of MN
activity, but no MN degeneration, and this effect does not
counterbalance the excitotoxic effects of chronic AMPA receptor
activation.
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